- Home
- SPPL vs MRNS Comparison
SPPL vs MRNS Comparison
Compare SPPL & MRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPPL
- MRNS
- Stock Information
- Founded
- SPPL 2016
- MRNS 2003
- Country
- SPPL Singapore
- MRNS United States
- Employees
- SPPL N/A
- MRNS N/A
- Industry
- SPPL
- MRNS Biotechnology: Pharmaceutical Preparations
- Sector
- SPPL
- MRNS Health Care
- Exchange
- SPPL Nasdaq
- MRNS Nasdaq
- Market Cap
- SPPL 14.8M
- MRNS 15.1M
- IPO Year
- SPPL 2023
- MRNS 2014
- Fundamental
- Price
- SPPL $0.80
- MRNS $0.23
- Analyst Decision
- SPPL
- MRNS Buy
- Analyst Count
- SPPL 0
- MRNS 12
- Target Price
- SPPL N/A
- MRNS $4.28
- AVG Volume (30 Days)
- SPPL 217.8K
- MRNS 1.0M
- Earning Date
- SPPL 12-31-2024
- MRNS 11-12-2024
- Dividend Yield
- SPPL N/A
- MRNS N/A
- EPS Growth
- SPPL N/A
- MRNS N/A
- EPS
- SPPL N/A
- MRNS N/A
- Revenue
- SPPL $3,550,862.00
- MRNS $31,466,000.00
- Revenue This Year
- SPPL N/A
- MRNS $15.71
- Revenue Next Year
- SPPL N/A
- MRNS $40.57
- P/E Ratio
- SPPL N/A
- MRNS N/A
- Revenue Growth
- SPPL N/A
- MRNS 1.63
- 52 Week Low
- SPPL $0.25
- MRNS $0.23
- 52 Week High
- SPPL $6.72
- MRNS $11.26
- Technical
- Relative Strength Index (RSI)
- SPPL 42.72
- MRNS 24.51
- Support Level
- SPPL $0.81
- MRNS $0.23
- Resistance Level
- SPPL $0.94
- MRNS $0.26
- Average True Range (ATR)
- SPPL 0.07
- MRNS 0.02
- MACD
- SPPL -0.04
- MRNS 0.02
- Stochastic Oscillator
- SPPL 12.15
- MRNS 0.00
About SPPL SIMPPLE LTD.
Simpple Ltd delivers an ecosystem solution that combines Internet-of-Things devices, robotic solutions and an integrated software system operating in unison to position buildings to be future-ready. The company operates through two primary segments: the sale, warranty, and maintenance of autonomous robotic cleaning equipment (Robots), and the sale of facilities management software. The majority of its revenue is generated from the Robots segment.
About MRNS Marinus Pharmaceuticals Inc.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.